Inactivated Vaccine Market – Competitive Landscape
Major players operating in the global inactivated vaccine market include GlaxoSmithKline Plc, Seqirus, Valneva SE, Pfizer Inc., Merck & Co., Inc., Emergent BioSolutions, Bharat Biotech, and Sanofi. Major market players are involved in adopting market strategies such as mergers, acquisitions, partnership, collaborations, and development of new products with leading companies and research institutes, in order to retain dominant position in the market. For instance, in 2017, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline Plc’s Shingrix, a zoster vaccine recombinant for the prevention of shingles in adults above the age of 50 years. Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses.
Inactivated Vaccine Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients